Literature DB >> 7086612

Growth hormone--dependent growth failure.

T Frazer, J R Gavin, W H Daughaday, R E Hillman, V V Weldon.   

Abstract

Growth failure may be associated with low serum somatomedin concentrations despite normal to increased concentrations of serum growth hormone. We have recognized five patients who responded to GH administration with an increase in serum Sm and an acceleration in skeletal growth, and have characterized the circulating GH in an homologous human GH radioreceptor assay employing the IM-9 lymphocyte as a source of human GH receptor. These five prepubertal children, who had a mean height 7.8 SD below the mean for age, had a mean RIA-GH of 34.2 +/- 3.5 ng/ml in response to stimulation, a basal Sm activity by hypophysectomized rat cartilage bioassay of less than 0.3 IU/ml, and a mean peak Sm of 0.9 +/- 0.1 IU/ml in response to 48 hours of GH therapy. During a one-year trial of GH therapy, four of these children significantly increased their growth velocity as compared to their growth rate before GH therapy. These children had a mean RIA-GH/RRA-GH ratio of 2.f. The fifth patient had a low RIA-GH/RRA-GH ratio and had no increase in growth rate. These studies suggest that growth in certain growth retarded children may be dependent on exogenous GH, even though they are not GH deficient by standard criteria.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7086612     DOI: 10.1016/s0022-3476(82)80171-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  12 in total

1.  Biologically inactive growth hormone caused by an amino acid substitution.

Authors:  Y Takahashi; H Shirono; O Arisaka; K Takahashi; T Yagi; J Koga; H Kaji; Y Okimura; H Abe; T Tanaka; K Chihara
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Profile of growth hormone deficiency in Bombay.

Authors:  M Desai; P Colaco; K P Sanghavi; C S Choksi; F E Vaz; M C Ambedkar
Journal:  Indian J Pediatr       Date:  1991 Sep-Oct       Impact factor: 1.967

3.  Biosynthetic growth hormone: whom to treat?

Authors:  M A Preece
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-08

Review 4.  Growth hormone therapy in Canada: end of one era and beginning of another.

Authors:  H J Dean; H G Friesen
Journal:  CMAJ       Date:  1986-08-15       Impact factor: 8.262

5.  Normal variant short stature.

Authors:  P S Menon; R K Menon; A Gupta
Journal:  Indian J Pediatr       Date:  1983 Sep-Oct       Impact factor: 1.967

6.  Who should get growth hormone?

Authors:  R D Milner
Journal:  Arch Dis Child       Date:  1984-12       Impact factor: 3.791

7.  Severe short stature and endogenous growth hormone resistance in twin brothers without growth hormone gene mutations.

Authors:  Emily C Walvoord; Kyle W Sloop; Conor J Dwyer; Simon J Rhodes; Ora H Pescovitz
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

8.  Assessment of growth hormone insulin like growth factor-I axis in Down's syndrome.

Authors:  A Barreca; A Rasore Quartino; M S Acutis; P Ponzani; G Damonte; E Miani; V Balestra; G Giordano; F Minuto
Journal:  J Endocrinol Invest       Date:  1994-06       Impact factor: 4.256

9.  Effectiveness of growth hormone (GH) therapy in GH-deficient children and non-GH-deficient short children.

Authors:  M Bozzola; M Cisternino; I Biscaldi; M Maghnie; A Valtorta; A Moretta; F Severi
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

10.  Human growth hormone therapy: longterm responses in 30 children with growth hormone deficiency.

Authors:  V Kannan; K Usharani
Journal:  Indian J Pediatr       Date:  1991 Sep-Oct       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.